Cheuk-Chun Szeto

List of Publications by Year
in descending order

476	19,888	12303	17546
papers	citations	h-index	g-index

487	487	487	16241
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. New England Journal of Medicine, 2003, 348, 1986-1994.	13.9	2,028
2	Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Peritoneal Dialysis International, 2010, 30, 393-423.	1.1	770
3	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. Peritoneal Dialysis International, 2016, 36, 481-508.	1.1	745
4	Circulating Endotoxemia. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 133-141.	2.2	388
5	ISPD Position Statement on Reducing the Risks of Peritoneal Dialysisâ€"Related Infections. Peritoneal Dialysis International, 2011, 31, 614-630.	1.1	273
6	Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY). Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 223-231.	2.2	271
7	Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis. Annals of Internal Medicine, 2003, 139, 105.	2.0	252
8	Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Archives of Internal Medicine, 2006, 166, 1975.	4.3	249
9	ISPD Catheter-Related Infection Recommendations: 2017 Update. Peritoneal Dialysis International, 2017, 37, 141-154.	1.1	239
10	Glomerular Filtration Rate, Cardiorenal End Points, and All-Cause Mortality in Type 2 Diabetic Patients. Diabetes Care, 2006, 29, 2046-2052.	4.3	196
11	Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney International, 2000, 58, 400-407.	2.6	190
12	The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. American Journal of Medicine, 2001, 110, 434-437.	0.6	186
13	Tuberculous Peritonitisâ€"Associated Mortality Is High among Patients Waiting for the Results of Mycobacterial Cultures of Ascitic Fluid Samples. Clinical Infectious Diseases, 2002, 35, 409-413.	2.9	186
14	Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Kidney Diseases, 2006, 47, 751-760.	2.1	177
15	Endotoxemia is Related to Systemic Inflammation and Atherosclerosis in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 431-436.	2.2	177
16	Serum and Urinary Cellâ€"free MiR-146a and MiR-155 in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2516-2522.	1.0	174
17	Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--A 1-year randomized control trial. Nephrology Dialysis Transplantation, 2006, 22, 552-559.	0.4	152
18	Prognostic indicators of IgA nephropathy in the Chineseâ€"clinical and pathological perspectives. Nephrology Dialysis Transplantation, 2002, 17, 64-69.	0.4	147

#	Article	IF	Citations
19	Risk factors for thiazide-induced hyponatraemia. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 911-917.	0.2	145
20	Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus, 2011, 20, 493-500.	0.8	142
21	Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 649-653.	1.3	141
22	Mitochondrial dysfunction in diabetic kidney disease. Clinica Chimica Acta, 2019, 496, 108-116.	0.5	137
23	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.3	136
24	Expression of microRNAs in the Urine of Patients With Bladder Cancer. Clinical Genitourinary Cancer, 2012, 10, 106-113.	0.9	134
25	Urinary miR-21, miR-29, and miR-93: Novel Biomarkers of Fibrosis. American Journal of Nephrology, 2012, 36, 412-418.	1.4	130
26	Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 2000, 36, 783-788.	2.1	128
27	A Risk Analysis of Continuous Ambulatory Peritoneal Dialysis-Related Peritonitis. Peritoneal Dialysis International, 2005, 25, 374-379.	1.1	127
28	Oral Sodium Bicarbonate for the Treatment of Metabolic Acidosis in Peritoneal Dialysis Patients: A Randomized Placebo-Control Trial. Journal of the American Society of Nephrology: JASN, 2003, 14, 2119-2126.	3.0	123
29	Renal Outcome in Type 2 Diabetic Patients With or Without Coexisting Nondiabetic Nephropathies. Diabetes Care, 2002, 25, 900-905.	4.3	118
30	Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scandinavian Journal of Rheumatology, 2002, 31, 296-300.	0.6	117
31	Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology, 2008, 47, 1678-1681.	0.9	115
32	Indication for peritoneal biopsy in tuberculous peritonitis. American Journal of Surgery, 2003, 185, 567-573.	0.9	113
33	Retrospective Review of Neurotoxicity Induced by Cefepime and Ceftazidime. Pharmacotherapy, 2003, 23, 369-373.	1.2	112
34	Elevated Levels of miR-146a and miR-155 in Kidney Biopsy and Urine from Patients with IgA Nephropathy. Disease Markers, 2011, 30, 171-179.	0.6	109
35	Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: A review of 104 cases. Kidney International, 2001, 59, 2309-2315.	2.6	108
36	Intrarenal Expression of miRNAs in Patients With Hypertensive Nephrosclerosis. American Journal of Hypertension, 2010, 23, 78-84.	1.0	107

#	Article	IF	Citations
37	Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus, 2004, 13, 601-604.	0.8	105
38	Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney International, 2019, 95, 178-187.	2.6	105
39	Intrarenal expression of microRNAs in patients with IgA nephropathy. Laboratory Investigation, 2010, 90, 98-103.	1.7	103
40	Peritoneal Dialysis Catheter Revision and Replacement by Nephrologist for Peritoneal Dialysis Catheter Malfunction. Nephron, 2018, 138, 214-219.	0.9	103
41	Enterobacteriaceae peritonitis complicating peritoneal dialysis: A review of 210 consecutive cases. Kidney International, 2006, 69, 1245-1252.	2.6	102
42	Feasibility of Resuming Peritoneal Dialysis after Severe Peritonitis and Tenckhoff Catheter Removal. Journal of the American Society of Nephrology: JASN, 2002, 13, 1040-1045.	3.0	101
43	Success of the peritoneal dialysis programme in Hong Kong. Nephrology Dialysis Transplantation, 2008, 23, 1475-1478.	0.4	100
44	Glomerular and tubulointerstitial miRâ€638, miRâ€198 and miRâ€146a expression in lupus nephritis. Nephrology, 2012, 17, 346-351.	0.7	99
45	Micro-RNA Expression in the Urinary Sediment of Patients with Chronic Kidney Diseases. Disease Markers, 2012, 33, 137-144.	0.6	98
46	Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrology Dialysis Transplantation, 2003, 18, 977-982.	0.4	97
47	Review Articles: Management Options for Hydrothorax Complicating Peritoneal Dialysis. Seminars in Dialysis, 2003, 16, 389-394.	0.7	96
48	StaphylococcusaureusPeritonitis Complicates Peritoneal Dialysis: Review of 245 Consecutive Cases. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 245-251.	2.2	94
49	New-Onset Hyperglycemia in Nondiabetic Chinese Patients Started on Peritoneal Dialysis. American Journal of Kidney Diseases, 2007, 49, 524-532.	2.1	94
50	Expression of MicroRNAs in the Urinary Sediment of Patients with IgA Nephropathy. Disease Markers, 2010, 28, 79-86.	0.6	93
51	Impact of Dialysis Adequacy on the Mortality and Morbidity of Anuric Chinese Patients Receiving Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 355-360.	3.0	93
52	Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 1999, 34, 1056-1064.	2.1	92
53	Nasal CPAP reduces systemic blood pressure in patients with obstructive sleep apnoea and mild sleepiness. Thorax, 2006, 61, 1083-1090.	2.7	91
54	Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. American Journal of Kidney Diseases, 2004, 43, 801-808.	2.1	89

#	Article	IF	Citations
55	Pathogenesis and management of hydrothorax complicating peritoneal dialysis. Current Opinion in Pulmonary Medicine, 2004, 10, 315-319.	1.2	89
56	Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled Trial. American Journal of Kidney Diseases, 2008, 51, 724-731.	2.1	87
57	Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology, 2000, 100, 217-224.	2.0	85
58	Carotid Intima Media Thickness Predicts Cardiovascular Diseases in Chinese Predialysis Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1966-1972.	3.0	85
59	Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Disease Markers, 2011, 30, 171-9.	0.6	85
60	Hypokalemia in Chinese Peritoneal Dialysis Patients: Prevalence and Prognostic Implication. American Journal of Kidney Diseases, 2005, 46, 128-135.	2.1	84
61	Peritoneal Dialysisâ€“Associated Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1100-1105.	2.2	80
62	The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology, 2009, 48, 1491-1497.	0.9	79
63	Podocyte Loss in Human Hypertensive Nephrosclerosis. American Journal of Hypertension, 2009, 22, 300-306.	1.0	79
64	Predictive Value of Dialysate Cell Counts in Peritonitis Complicating Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 768-773.	2.2	78
65	Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clinical Rheumatology, 2012, 31, 435-440.	1.0	77
66	The clinical course of culture-negative peritonitis complicating peritoneal dialysis. American Journal of Kidney Diseases, 2003, 42, 567-574.	2.1	73
67	Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis and Rheumatism, 2004, 50, 2882-2890.	6.7	73
68	Intrarenal cytokine gene expression in lupus nephritis. Annals of the Rheumatic Diseases, 2007, 66, 886-892.	0.5	72
69	MicroRNAs in IgA nephropathy. Nature Reviews Nephrology, 2014, 10, 249-256.	4.1	71
70	Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut, 2020, 69, 617-629.	6.1	71
71	Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Disease Markers, 2010, 28, 79-86.	0.6	71
72	Comparison of clinical outcome and ease of handling in two double-bag systems in continuous ambulatory peritoneal dialysis: A prospective, randomized, controlled, multicenter study. American Journal of Kidney Diseases, 2002, 40, 373-380.	2.1	70

#	Article	IF	Citations
73	Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in south-east Asia. Clinical Microbiology and Infection, 2005, 11, 837-839.	2.8	70
74	Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis and Rheumatism, 2003, 48, 1326-1331.	6.7	69
75	Rosiglitazone Reduces Insulin Requirement and C-Reactive Protein Levels in Type 2 Diabetic Patients Receiving Peritoneal Dialysis. American Journal of Kidney Diseases, 2005, 46, 713-719.	2.1	68
76	Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric diseases. Clinica Chimica Acta, 2005, 361, 182-190.	0.5	68
77	Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. American Journal of Kidney Diseases, 1999, 34, 1132-1136.	2.1	67
78	Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney International, 2004, 65, 1947-1955.	2.6	67
79	Messenger RNA Expression of Podocyte-Associated Molecules in the Urinary Sediment of Patients with Diabetic Nephropathy. Nephron Clinical Practice, 2007, 106, c169-c179.	2.3	67
80	Associations between microRNA (miR-21, 126, 155 and 221), albuminuria and heavy metals in Hong Kong Chinese adolescents. Clinica Chimica Acta, 2012, 413, 1053-1057.	0.5	67
81	Cell-Free Urinary MicroRNA-99a and MicroRNA-125b Are Diagnostic Markers for the Non-Invasive Screening of Bladder Cancer. PLoS ONE, 2014, 9, e100793.	1.1	67
82	Peritoneal Dialysis as the First-line Renal Replacement Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2011, 57, 903-907.	2.1	66
83	A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Peritoneal Dialysis International, 2005, 25, 374-9.	1.1	66
84	Good Patient and Technique Survival in Elderly Patients on Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 2007, 27, 196-201.	1.1	65
85	Predictors of Residual Renal Function Decline in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 2015, 35, 180-188.	1.1	65
86	Outcome of IgA nephropathy in adults graded by chronic histological lesions. American Journal of Kidney Diseases, 2000, 35, 392-400.	2.1	64
87	Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology, 2009, 48, 892-898.	0.9	64
88	Long-term treatment of lupus nephritis with cyclosporin A. QJM - Monthly Journal of the Association of Physicians, 1998, 91, 573-580.	0.2	63
89	Peritoneal Transport Status Correlates With Morbidity But Not Longitudinal Change of Nutritional Status of Continuous Ambulatory Peritoneal Dialysis Patients: A 2-Year Prospective Study. American Journal of Kidney Diseases, 2001, 37, 329-336.	2.1	63
90	Influence of Peritoneal Dialysis Training Nurses' Experience on Peritonitis Rates. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 647-652.	2.2	63

#	Article	IF	Citations
91	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. Clinical Chemistry, 2017, 63, 1614-1623.	1.5	63
92	Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment. American Journal of Kidney Diseases, 2009, 54, 702-710.	2.1	62
93	Antibody Response to Hepatitis B Vaccine in End-Stage Renal Disease Patients. Nephron Clinical Practice, 2006, 103, c89-c93.	2.3	61
94	A whitened face woman with nephrotic syndrome. American Journal of Kidney Diseases, 2003, 41, 250-253.	2.1	60
95	Bioimpedance Spectroscopy for the Detection of Fluid Overload in Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2014, 34, 409-416.	1.1	60
96	Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clinical Biochemistry, 2017, 50, 496-501.	0.8	60
97	Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis: A randomized prospective multicenter study. American Journal of Kidney Diseases, 1999, 33, 535-540.	2.1	59
98	Prognostic value of renal function in patients with cardiac resynchronization therapy. International Journal of Cardiology, 2007, 122, 10-16.	0.8	59
99	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Alimentary Pharmacology and Therapeutics, 2018, 48, 984-992.	1.9	59
100	Coagulase Negative Staphylococcal Peritonitis in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 91-97.	2.2	57
101	Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney International, 2000, 57, 632-638.	2.6	56
102	Conservative management of polymicrobial peritonitis complicating peritoneal dialysisâ€"a series of 140 consecutive cases. American Journal of Medicine, 2002, 113, 728-733.	0.6	56
103	Mechanisms of antibiotic neurotoxicity in renal failure. International Journal of Antimicrobial Agents, 2004, 23, 213-217.	1.1	56
104	Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2019, 34, 2118-2126.	0.4	56
105	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney International, 2005, 67, S2-S7.	2.6	55
106	Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Annals of the Rheumatic Diseases, 2006, 65, 417-418.	0.5	55
107	Severe Acute Respiratory Syndrome in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 1883-1888.	3.0	54
108	Hydrothorax Complicating Peritoneal Dialysis: Diagnostic Value of Glucose Concentration in Pleural Fluid Aspirate. Peritoneal Dialysis International, 2002, 22, 525-527.	1.1	52

#	Article	IF	Citations
109	Nonconvulsive status epilepticus in peritoneal dialysis patients. American Journal of Kidney Diseases, 2001, 38, 400-405.	2.1	50
110	Isolate diffuse thickening of glomerular capillary basement membrane: a renal lesion in prediabetes?. Modern Pathology, 2004, 17, 1506-1512.	2.9	50
111	Gene expression of TWEAK/Fn14 and IPâ€10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology, 2011, 16, 426-432.	0.7	50
112	Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: Their relationship with transport parameters. American Journal of Kidney Diseases, 1997, 29, 699-705.	2.1	49
113	Messenger RNA expression of target genes in the urinary sediment of patients with chronic kidney diseases. Nephrology Dialysis Transplantation, 2005, 20, 105-113.	0.4	49
114	Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology, 2006, 46, 649-652.	0.9	49
115	Urinary sediment miRNA levels in adult nephrotic syndrome. Clinica Chimica Acta, 2013, 418, 5-11.	0.5	49
116	Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 784-788.	0.4	49
117	Adequacy Targets of Peritoneal Dialysis in the Asian Population. Peritoneal Dialysis International, 2001, 21, 378-383.	1.1	47
118	Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia, 2008, 51, 1062-1067.	2.9	47
119	Growth Factors in Continuous Ambulatory Peritoneal Dialysis Effluent. American Journal of Nephrology, 1999, 19, 416-422.	1.4	46
120	Association of transforming growth factor-beta (TGF-Î²) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney International, 2003, 63, 1831-1835.	2.6	46
121	Asymptomatic isolated microscopic haematuria: long-term follow-up. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 739-745.	0.2	46
122	Peritoneal Albumin Excretion is a Strong Predictor of Cardiovascular Events in Peritoneal Dialysis Patients: A Prospective Cohort Study. Peritoneal Dialysis International, 2005, 25, 445-452.	1.1	46
123	The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrology Dialysis Transplantation, 2006, 21, 1534-1540.	0.4	46
124	Predicting 12-Month Mortality for Peritoneal Dialysis Patients Using the â€œSurpriseâ€•Question. Peritoneal Dialysis International, 2013, 33, 60-66.	1.1	45
125	Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD. American Journal of Kidney Diseases, 1999, 33, 318-324.	2.1	44
126	Influence of Climate on the Incidence of Peritoneal Dialysis-Related Peritonitis. Peritoneal Dialysis International, 2003, 23, 580-586.	1.1	44

#	Article	IF	Citations
127	Urinary Expression of Kidney Injury Markers in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2329-2337.	2.2	44
128	Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. Journal of Rheumatology, 2007, 34, 2358-64.	1.0	43
129	Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. European Journal of Endocrinology, 2008, 158, 317-322.	1.9	42
130	A prospective cohort study of the long-term effects of CPAP on carotid artery intima-media thickness in Obstructive sleep apnea syndrome. Respiratory Research, 2012, 13, 22.	1.4	42
131	Geriatric Nutritional Risk Index as a Screening Tool for Malnutrition in Patients on Chronic Peritoneal Dialysis. , 2010, 20, 29-37.		41
132	Urine miRNA in nephrotic syndrome. Clinica Chimica Acta, 2014, 436, 308-313.	0.5	41
133	Xanthomonas maltophilia peritonitis in uremic patients receiving continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 1997, 29, 91-95.	2.1	40
134	Longitudinal Study of Peritoneal Membrane Function in Continuous Ambulatory Peritoneal Dialysis: Relationship with Peritonitis and Fibrosing Factors. Peritoneal Dialysis International, 2000, 20, 679-685.	1.1	40
135	Independent Effects of Renal and Peritoneal Clearances on the Mortality of Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2004, 24, 58-64.	1.1	39
136	Discrepancy between Intrarenal Messenger RNA and Protein Expression of ACE and ACE2 in Human Diabetic Nephropathy. American Journal of Nephrology, 2009, 29, 524-531.	1.4	39
137	Repeat Renal Biopsy in Lupus Nephritis: A Change in Histological Pattern Is Common. American Journal of Nephrology, 2011, 34, 220-225.	1.4	39
138	Prognostic Value of Arterial Pulse Wave Velocity in Peritoneal Dialysis Patients. American Journal of Nephrology, 2012, 35, 127-133.	1.4	39
139	Impact of social factors on patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2005, 20, 2504-2510.	0.4	38
140	Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes. Kidney International, 2006, 69, 383-387.	2.6	38
141	Urinary sediment ICAM-1 level in lupus nephritis. Lupus, 2012, 21, 1190-1195.	0.8	38
142	Asymptomatic fluid overload predicts survival and cardiovascular event in incident Chinese peritoneal dialysis patients. PLoS ONE, 2018, 13, e0202203.	1.1	38
143	Cefazolin plus Ceftazidime versus Imipenem / Cilastatin Monotherapy for Treatment of Capd Peritonitis â€" a Randomized Controlled Trial. Peritoneal Dialysis International, 2004, 24, 440-446.	1.1	37
144	Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: A review of 104 cases. Kidney International, 2001, 59, 2309.	2.6	37

#	Article	IF	Citations
145	Nephrotic Syndrome in Strongyloidiasis: Remission after Eradication with Anthelmintic Agents. Nephron, 1998, 79, 333-336.	0.9	36
146	Use of Intraperitoneal Cefepime as Monotherapy in Treatment of CAPD Peritonitis. Peritoneal Dialysis International, 2000, 20, 232-234.	1.1	36
147	Circulating bacterial-derived DNA fragments as a marker * of systemic inflammation in peritoneal dialysis. Nephrology Dialysis Transplantation, 2013, 28, 2139-2145.	0.4	35
148	Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. BMC Family Practice, 2014, 15, 8.	2.9	35
149	Long-term Outcome of Biopsy-Proven Minimal Change Nephropathy in Chinese Adults. American Journal of Kidney Diseases, 2015, 65, 710-718.	2.1	35
150	Characterization of early IgA nephropathy. American Journal of Kidney Diseases, 2000, 36, 703-708.	2.1	34
151	Differential Effects of Transforming Growth Factor-Beta on the Synthesis of Connective Tissue Growth Factor and Vascular Endothelial Growth Factor by Peritoneal Mesothelial Cell. Nephron Experimental Nephrology, 2005, 99, e95-e104.	2.4	34
152	Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare. Rheumatology, 2007, 46, 44-48.	0.9	34
153	Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1601-1608.	3.0	34
154	Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis. Seminars in Nephrology, 2017, 37, 30-42.	0.6	33
155	Elevation of Pro-Inflammatory Cytokines, C-Reactive Protein and Cardiac Troponin T in Chronic Renal Failure Patients on Dialysis. Immunological Investigations, 2007, 36, 47-57.	1.0	32
156	Bacteria-Derived DNA Fragment in Peritoneal Dialysis Effluent as a Predictor of Relapsing Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1935-1941.	2.2	31
157	Cardiovascular Protective Effects of Adjunctive Alternative Medicine (<i>Salvia) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 267 Td [m and Alternative Medicine, 2013, 2013, 1-8.	0.5	31
158	Circulating Bacterial-Derived DNA Fragment Level Is a Strong Predictor of Cardiovascular Disease in Peritoneal Dialysis Patients. PLoS ONE, 2015, 10, e0125162.	1.1	31
159	Repeat Peritonitis in Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 827-833.	2.2	30
160	Frailty in Chinese Peritoneal Dialysis Patients: Prevalence and Prognostic Significance. Kidney and Blood Pressure Research, 2016, 41, 736-745.	0.9	30
161	Straight Versus Coiled Peritoneal Dialysis Catheters: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2020, 75, 39-44.	2.1	30
162	Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response. Rheumatology, 2009, 48, 755-760.	0.9	29

#	Article	IF	Citations
163	In Reply to â€˜Peritoneal Dialysis for Patients With Polycystic Kidney Disease in Spainâ€™ and â€˜Do the Benefits of Peritoneal Dialysis for Polycystic Kidney Disease Wane With Time?â€™. American Journal of Kidney Diseases, 2011, 58, 494.	2.1	29
164	Grading of Acute and Chronic Renal Lesions in Henoch-SchÃ¶nlein Purpura. Modern Pathology, 2001, 14, 635-640.	2.9	28
165	Metabolic Acidosis and Malnutrition in Dialysis Patients. Seminars in Dialysis, 2004, 17, 371-375.	0.7	28
166	Expression of ACE and ACE2 in Patients with Hypertensive Nephrosclerosis. Kidney and Blood Pressure Research, 2011, 34, 141-149.	0.9	28
167	Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Research and Therapy, 2012, 14, R80.	1.6	28
168	Peritoneal Dialysis-Related Infection in the Older Population. Peritoneal Dialysis International, 2015, 35, 659-662.	1.1	28
169	Peritoneal albumin excretion is a strong predictor of cardiovascular events in peritoneal dialysis patients: a prospective cohort study. Peritoneal Dialysis International, 2005, 25, 445-52.	1.1	28
170	Posttransplant Epstein-Barr virus-associated myogenic tumors involving bone. Cancer, 2000, 89, 467-472.	2.0	27
171	Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus, 2003, 12, 665-671.	0.8	27
172	The clinical course of peritoneal dialysis-related peritonitis caused by Corynebacterium species. Nephrology Dialysis Transplantation, 2005, 20, 2793-2796.	0.4	27
173	Comprehensive malnutrition inflammation score as a marker of nutritional status in Chinese peritoneal dialysis patients. Nephrology, 2007, 12, 130-134.	0.7	27
174	Use of low-dose low molecular weight heparin in hemodialysis. American Journal of Kidney Diseases, 1996, 28, 721-726.	2.1	26
175	The Role of Lean Body Mass as a Nutritional Index in Chinese Peritoneal Dialysis Patientsâ€”Comparison of Creatinine Kinetics Method and Anthropometric Method. Peritoneal Dialysis International, 2000, 20, 708-714.	1.1	26
176	Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis. Nephrology, 2006, 11, 219-225.	0.7	26
177	Tenckhoff Catheter Insertion by Nephrologists: Open Dissection Technique. Peritoneal Dialysis International, 2010, 30, 524-527.	1.1	26
178	Circulating Endotoxaemia and Frequent Haemodialysis Schedules. Nephron Clinical Practice, 2014, 128, 141-146.	2.3	26
179	Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 507-512.	1.4	26
180	Urinary miRNA profile for the diagnosis of IgA nephropathy. BMC Nephrology, 2019, 20, 77.	0.8	26

#	Article	IF	Citations
181	Gram-Negative Peritonitisâ€"The Achilles Heel of Peritoneal Dialysis?. Peritoneal Dialysis International, 2007, 27, 267-271.	1.1	26
182	Contribution of gene polymorphisms in the renin-angiotensin system to macroangiopathy in patients with diabetic nephropathy. American Journal of Kidney Diseases, 2001, 38, 9-17.	2.1	25
183	Association of ENOS polymorphism with basal peritoneal membrane function in uremic patients. American Journal of Kidney Diseases, 2003, 42, 781-786.	2.1	25
184	mRNA Expression of Target Genes in the Urinary Sediment as a Noninvasive Prognostic Indicator of CKD. American Journal of Kidney Diseases, 2006, 47, 578-586.	2.1	25
185	Fatal Pancytopenia in a Hemodialysis Patient After Treatment With Low-Dose Methotrexate. Journal of Clinical Rheumatology, 2009, 15, 177-180.	0.5	25
186	Mineralocorticoid Receptor Antagonist for Renal Protection. Renal Failure, 2012, 34, 810-817.	0.8	25
187	Depression and Physical Frailty Have Additive Effect on the Nutritional Status and Clinical Outcome of Chinese Peritoneal Dialysis. Kidney and Blood Pressure Research, 2018, 43, 914-923.	0.9	25
188	Good patient and technique survival in elderly patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International, 2007, 27 Suppl 2, S196-201.	1.1	25
189	Near-miss errors in laboratory blood test requests by interns. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 753-756.	0.2	24
190	Nephrotoxicity Related to New Therapeutic Compounds. Renal Failure, 2005, 27, 329-333.	0.8	24
191	Urinary mononuclear cell and disease activity of systemic lupus erythematosus. Lupus, 2006, 15, 262-267.	0.8	24
192	Treatment of Metabolic Syndrome in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 149-152.	1.1	24
193	Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor. American Journal of Medicine, 2013, 126, 162-168.	0.6	24
194	Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1438-1443.	0.4	24
195	Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis. Arthritis and Rheumatology, 2019, 71, 271-280.	2.9	24
196	Transition between Different Renal Replacement Modalities: Gaps in Knowledge and Careâ€"the Integrated Research Initiative. Peritoneal Dialysis International, 2019, 39, 4-12.	1.1	24
197	Dialysate hyaluronan concentration predicts survival but not peritoneal sclerosis in continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 2000, 36, 609-614.	2.1	23
198	Continuous Ambulatory Peritoneal Dialysis Peritonitis: Broth Inoculation Culture versus Water Lysis Method. Nephron Clinical Practice, 2007, 105, c121-c125.	2.3	23

#	Article	IF	Citations
199	Quantification of gene expression in urinary sediment for the study of renal diseases. Nephrology, 2007, 12, 494-499.	0.7	23
200	Effect of Membrane Permeability on Inflammation and Arterial Stiffness. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 652-658.	2.2	23
201	Metabolic Syndrome in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 779-787.	2.2	23
202	Urinary mitochondrial DNA level in non-diabetic chronic kidney diseases. Clinica Chimica Acta, 2018, 484, 36-39.	0.5	23
203	Independent effects of renal and peritoneal clearances on the mortality of peritoneal dialysis patients. Peritoneal Dialysis International, 2004, 24, 58-64.	1.1	23
204	Decreased T-bet expression and changes in chemokine levels in adults with asthma. Clinical and Experimental Immunology, 2007, 147, 526-532.	1.1	22
205	Impact of Early Nephrology Referral on Mortality and Hospitalization in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 371-376.	1.1	22
206	Genetic and clinical variables identify predictors forÂchronic kidney disease in type 2 diabetes. Kidney International, 2016, 89, 411-420.	2.6	22
207	Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak. Annals of the Rheumatic Diseases, 2021, 80, e97-e97.	0.5	22
208	Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy. American Journal of Kidney Diseases, 1998, 32, 813-819.	2.1	21
209	Advances in the clinical laboratory assessment of urinary sediment. Clinica Chimica Acta, 2004, 340, 67-78.	0.5	21
210	Transforming Growth Factor-Î²1 Gene Polymorphism in Renal Transplant Recipients. Renal Failure, 2005, 27, 671-675.	0.8	21
211	Endotoxemia is Associated with Better Clinical Outcome in Incident Chinese Peritoneal Dialysis Patients: A Prospective Cohort Study. Peritoneal Dialysis International, 2010, 30, 178-186.	1.1	21
212	Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Lupus, 2015, 24, 675-686.	0.8	21
213	Diabetic Muscle Infarction: Myocardial infarct equivalent. Diabetes Care, 2002, 25, 1895-1895.	4.3	20
214	Primary IgA nephropathy with low histologic grade and disease progression: Is there a â€œpoint of no returnâ€?. American Journal of Kidney Diseases, 2002, 39, 401-406.	2.1	20
215	Multifocal myoclonus secondary to tranexamic acid. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 547-547.	0.9	20
216	Body mass index as a predictive factor for long-term renal transplant outcomes in Asians. Clinical Transplantation, 2006, 20, 582-589.	0.8	20

#	Article	IF	Citations
217	Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrology Dialysis Transplantation, 2007, 22, 1697-1702.	0.4	20
218	Increasing home based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Nephrology, 2011, 16, 53-56.	0.7	20
219	Methods of MicroRNA Quantification in Urinary Sediment. Methods in Molecular Biology, 2013, 1024, 211-220.	0.4	20
220	Peritoneal protein clearance predicts mortality in peritoneal dialysis patients. Clinical and Experimental Nephrology, 2019, 23, 551-560.	0.7	20
221	Connective Tissue Growth Factor Is Responsible for Transforming Growth Factor-Beta-Induced Peritoneal Mesothelial Cell Apoptosis. Nephron Experimental Nephrology, 2006, 103, e166-e174.	2.4	19
222	Cerebral atrophy and skull thickening due to chronic phenytoin therapy. Cmaj, 2007, 176, 321-323.	0.9	19
223	Peroxisome Proliferator-Activated Receptor-Gamma Gene Polymorphism and Risk of Cardiovascular Disease in Patients with Diabetic Nephropathy. American Journal of Nephrology, 2008, 28, 715-722.	1.4	19
224	The Impact of Social Support on the Survival of Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2008, 28, 252-258.	1.1	19
225	Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss. Renal Failure, 2010, 32, 372-379.	0.8	19
226	Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production. PLoS ONE, 2011, 6, e23855.	1.1	19
227	The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy â€“ A Randomized Cross-Over Study. PLoS ONE, 2013, 8, e62736.	1.1	19
228	Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. Nephrology, 2017, 22, 316-321.	0.7	19
229	Influence of climate on the incidence of peritoneal dialysis-related peritonitis. Peritoneal Dialysis International, 2003, 23, 580-6.	1.1	19
230	The Impact of Increasing the Daytime Dialysis Exchange Frequency on Peritoneal Dialysis Adequacy and Nutritional Status of Chinese Anuric Patients. Peritoneal Dialysis International, 2002, 22, 197-203.	1.1	18
231	The Role of Vascular Endothelial Growth Factor in Peritoneal Hyperpermeability during CAPD-Related Peritonitis. Peritoneal Dialysis International, 2002, 22, 265-267.	1.1	18
232	Continuous Ambulatory Peritoneal Dialysis in Patients with Hepatitis B Liver Disease. Peritoneal Dialysis International, 2006, 26, 213-217.	1.1	18
233	Cross sectional survey on the concerns and anxiety of patients waiting for organ transplants. Nephrology, 2012, 17, 514-518.	0.7	18
234	Effect of Using Ultrapure Dialysate for Hemodialysis on the Level of Circulating Bacterial Fragment in Renal Failure Patients. Nephron Clinical Practice, 2013, 123, 246-253.	2.3	18

#	Article	IF	Citations
235	Urinary mitochondrial DNA level as a biomarker of tissue injury in non-diabetic chronic kidney diseases. BMC Nephrology, 2018, 19, 367.	0.8	18
236	Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2019, 44, 1259-1270.	0.9	18
237	Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians. Genome Medicine, 2021, 13, 29.	3.6	18
238	Interaction between central obesity and frailty on the clinical outcome of peritoneal dialysis patients. PLoS ONE, 2020, 15, e0241242.	1.1	18
239	Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong. Journal of Rheumatology, 2008, 35, 1031-7.	1.0	18
240	Measured-to-predicted creatinine generation ratio increases with time and decline in residual renal function in continuous ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 1999, 34, 235-241.	2.1	17
241	Severe acute respiratory syndrome in a hemodialysis patient. American Journal of Kidney Diseases, 2003, 42, 1069-1074.	2.1	17
242	Peritonealâ€dialysis related peritonitis caused by <scp>G</scp>ordonia species: Report of four cases and literature review. Nephrology, 2014, 19, 379-383.	0.7	17
243	Urinary mRNA levels of ELRâ€negative CXC chemokine ligand and extracellular matrix in diabetic nephropathy. Diabetes/Metabolism Research and Reviews, 2015, 31, 699-706.	1.7	17
244	The Effect of Neutral Peritoneal Dialysis Solution with Low Glucose-Degradation-Product on the Fluid Status and Body Composition â€“ A Randomized Control Trial. PLoS ONE, 2015, 10, e0141425.	1.1	17
245	Urinary Mitochondrial DNA Level as a Biomarker of Acute Kidney Injury Severity. Kidney Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Ov	1.2	17
246	Peritoneal dialysis-related peritonitis caused by Pseudomonas species: Insight from a post-millennial case series. PLoS ONE, 2018, 13, e0196499.	1.1	17
247	Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial. Peritoneal Dialysis International, 2004, 24, 440-6.	1.1	17
248	Effect of a compensated JaffÃ© creatinine method on the estimation of glomerular filtration rate. Annals of Clinical Biochemistry, 2004, 41, 482-484.	0.8	16
249	Longitudinal Changes of Cardiothoracic Ratio and Vascular Pedicle Width as Predictors of Volume Status during One Year in Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2009, 32, 45-50.	0.9	16
250	Relation between MicroRNA Expression in Peritoneal Dialysis Effluent and Peritoneal Transport Characteristics. Disease Markers, 2012, 33, 35-42.	0.6	16
251	Remote ischaemic preâ€conditioning for the prevention of acute kidney injury. Nephrology, 2016, 21, 274-285.	0.7	16
252	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. Journal of the American Society of Nephrology: JASN, 2021, 32, 961-971.	3.0	16

#	Article	IF	Citations
253	Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus, 2001, 10, 827-829.	0.8	15
254	Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. Nephrology Dialysis Transplantation, 2010, 25, 2303-2309.	0.4	15
255	The Impact of Antihypertensive Drug Therapy on Endotoxemia in Elderly Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2389-2394.	2.2	15
256	Automated peritoneal dialysis in <scp>H</scp>ong <scp>K</scp>ong: There are two distinct groups of patients. Nephrology, 2013, 18, 356-364.	0.7	15
257	Peritonitis before Peritoneal Dialysis Training: Analysis of Causative Organisms, Clinical Outcomes, Risk Factors, and Long-Term Consequences. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1219-1226.	2.2	15
258	The role of obesity on chronic kidney disease development, progression, and cardiovascular complications. Advances in Biomarker Sciences and Technology, 2020, 2, 24-34.	0.8	15
259	Chromosomal telomere shortening of kidney cells in IgA nephropathy by the measurement of DNA in urinary sediment. Clinical Nephrology, 2005, 64, 337-342.	0.4	15
260	Treatment of metabolic syndrome in peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29 Suppl 2, S149-52.	1.1	15
261	Acute renal failure in a patient with Rosai-Dorfman disease. American Journal of Kidney Diseases, 1999, 34, e12.1-e12.6.	2.1	14
262	Adherence to peritoneal dialysis training schedule. Nephrology Dialysis Transplantation, 2006, 22, 545-551.	0.4	14
263	Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. Lupus, 2006, 15, 276-281.	0.8	14
264	Outcome of Hemodialysis Patients Who Had Failed Peritoneal Dialysis. Nephron Clinical Practice, 2010, 116, c300-c306.	2.3	14
265	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. Journal of Rheumatology, 2015, 42, 1150-1155.	1.0	14
266	Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. CKJ: Clinical Kidney Journal, 2016, 9, 616-623.	1.4	14
267	Causes of nephrotic syndrome and nephroticâ€range proteinuria are different in adult Chinese patients: A single centre study over 33Âyears. Nephrology, 2018, 23, 565-572.	0.7	14
268	Metabolomic Changes of Human Proximal Tubular Cell Line in High Glucose Environment. Scientific Reports, 2019, 9, 16617.	1.6	14
269	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Reports, 2020, 5, 1129-1138.	0.4	14
270	Gram-negative peritonitis--the Achilles heel of peritoneal dialysis?. Peritoneal Dialysis International, 2007, 27 Suppl 2, S267-71.	1.1	14

#	Article	IF	Citations
271	Association of IgA nephropathy with T-cell receptor constant alpha chain gene polymorphism. American Journal of Kidney Diseases, 1997, 30, 260-264.	2.1	13
272	Increased ascitic level of hyaluronan in liver cirrhosis. Translational Research, 1998, 131, 354-359.	2.4	13
273	Extrapolation of reciprocal creatinine plot is not reliable in predicting the onset of dialysis in patients with progressive renal insufficiency. Journal of Internal Medicine, 2003, 253, 335-342.	2.7	13
274	Genetic Polymorphism of Vascular Endothelial Growth Factor: Impact on Progression of IgA Nephropathy. Renal Failure, 2006, 28, 15-20.	0.8	13
275	Influence of climate on the incidence of thiazide-induced hyponatraemia. International Journal of Clinical Practice, 2006, 61, 449-452.	0.8	13
276	Revascularization for post-transplant renal artery stenosis. Nephrology, 2007, 12, 406-412.	0.7	13
277	Unexplained Exudative Pleural Effusion in Chronic Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2010, 30, 534-540.	1.1	13
278	Life expectancy of Chinese patients with chronic kidney disease without dialysis. Nephrology, 2011, 16, 715-719.	0.7	13
279	Relationship of Intrarenal Gene Expression and the Histological Class of Lupus Nephritis â€" A Study on Repeat Renal Biopsy. Journal of Rheumatology, 2012, 39, 1942-1947.	1.0	13
280	Monitoring of urinary messenger RNA levels for the prediction of flare in systemic lupus erythematosus. Clinica Chimica Acta, 2012, 413, 448-455.	0.5	13
281	Fracture risk after thiazideâ€associated hyponatraemia. Internal Medicine Journal, 2012, 42, 760-764.	0.5	13
282	Helper-assisted continuous ambulatory peritoneal dialysis: Does the choice of helper matter?. Peritoneal Dialysis International, 2020, 40, 34-40.	1.1	13
283	Urinary podocyte markers in kidney diseases. Clinica Chimica Acta, 2021, 523, 315-324.	0.5	13
284	Shared Decision-Making for a Dialysis Modality. Kidney International Reports, 2022, 7, 15-27.	0.4	13
285	Plasminogen activator inhibitor-1 4G/5G genetic polymorphism does not affect peritoneal transport characteristic. American Journal of Kidney Diseases, 2002, 39, 1061-1067.	2.1	12
286	Association of interleukinâ€18 promoter polymorphism and atherosclerotic diseases in Chinese patients with diabetic nephropathy. Nephrology, 2009, 14, 606-612.	0.7	12
287	Arterial Pulse Wave Velocity and Peritoneal Transport Characteristics Independently Predict Hospitalization in Chinese Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2010, 30, 80-85.	1.1	12
288	Persistent Symptomatic Intra-Abdominal Collection after Catheter Removal for Pd-Related Peritonitis. Peritoneal Dialysis International, 2011, 31, 34-38.	1.1	12

#	Article	IF	Citations
289	Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank. American Journal of Kidney Diseases, 2022, 80, 196-206.e1.	2.1	12
290	Rhodococcus equi peritonitis in continuous ambulatory peritoneal dialysis. Journal of Nephrology, 2003, 16, 736-9.	0.9	12
291	Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: Relationships with insulin requirement. American Journal of Kidney Diseases, 1999, 34, 514-520.	2.1	11
292	Dialysis adequacy and transport test for characterization of peritoneal transport type in chinese peritoneal dialysis patients receiving three daily exchanges. American Journal of Kidney Diseases, 2002, 39, 1287-1291.	2.1	11
293	Serial monitoring of nutritional status in Chinese peritoneal dialysis patients by Subjective Global Assessment and comprehensive Malnutrition Inflammation Score. Nephrology, 2009, 14, 143-147.	0.7	11
294	Increasing homeâ€based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. Hemodialysis International, 2011, 15, 10-14.	0.4	11
295	RelationshipbetweenCRPPolymorphism and Cardiovascular Events in Chinese Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 304-309.	2.2	11
296	Peritonitis Rates of the Past Thirty Years: From Improvement to Stagnation. Peritoneal Dialysis International, 2014, 34, 151-153.	1.1	11
297	Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clinica Chimica Acta, 2017, 464, 106-112.	0.5	11
298	Treatment of Enterococcal Peritonitis in Peritoneal Dialysis Patients by Oral Amoxicillin or Intra-Peritoneal Vancomcyin: a Retrospective Study. Kidney and Blood Pressure Research, 2017, 42, 837-843.	0.9	11
299	Trends in kidney failure and kidney replacement therapy in people with diabetes in Hong Kong, 2002-2015: A retrospective cohort study. The Lancet Regional Health - Western Pacific, 2021, 11, 100165.	1.3	11
300	Impact of frailty and its inter-relationship with lean tissue wasting and malnutrition on kidney transplant waitlist candidacy and delisting. Clinical Nutrition, 2021, 40, 5620-5629.	2.3	11
301	Mixed isopropanol-methanol intoxication following ingestion of alcohol-based hand rubÂsolution. Clinical Nephrology, 2017, 88, 218-220.	0.4	11
302	Exogenous type-1 cytokines modulate mercury-induced hyper-IgE in the rat. Clinical and Experimental Immunology, 2000, 121, 17-22.	1.1	10
303	Antiproteinuric and antiâ€inflammatory effects of thiazolidinedione (Review Article). Nephrology, 2008, 13, 53-57.	0.7	10
304	Metabolic syndrome in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2008, 1, 206-214.	1.4	10
305	Hypokalaemia and cardiac risk in peritoneal dialysis patients. Nature Reviews Nephrology, 2012, 8, 501-503.	4.1	10
306	Progression in Physical Frailty in Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2021, 46, 342-351.	0.9	10

#	Article	IF	Citations
307	The change in the prevalence of obesity and new-onset diabetes in Chinese peritoneal dialysis patients over 25 years. CKJ: Clinical Kidney Journal, 2022, 15, 70-78.	1.4	10
308	Can the urine dipstick test reduce the need for microscopy for assessment of systemic lupus erythematosus disease activity?. Journal of Rheumatology, 2005, 32, 828-31.	1.0	10
309	Prognostic role of serum ACE activity on outcome of type 2 diabetic patients on chronic ambulatory peritoneal dialysis. American Journal of Kidney Diseases, 2002, 39, 1054-1060.	2.1	9
310	Peritoneal Dialysis Adequacy in Asiaâ€"Is Higher Better?. Peritoneal Dialysis International, 2003, 23, 65-68.	1.1	9
311	Nephrotoxicity Related to New Therapeutic Compounds. Renal Failure, 2005, 27, 329-333.	0.8	9
312	Impact of enforcing the Labour Ordinance, with 1-in-7-day off for hospital doctors, on weekend hospital discharge rate. Journal of Public Health, 2005, 27, 189-191.	1.0	9
313	Residual Renal Function and Recovery of Renal Function. Peritoneal Dialysis International, 2007, 27, 159-161.	1.1	9
314	A Lady with Rapid Onset of Swollen Parotid Glands. Southern Medical Journal, 2008, 101, 428-431.	0.3	9
315	Playing Cat and Mouse with a Gram-Negative Organism Causing Peritonitis. Peritoneal Dialysis International, 2010, 30, 662-663.	1.1	9
316	Open Surgical Insertion of Tenckhoff Catheters for Peritoneal Dialysis. Peritoneal Dialysis International, 2010, 30, 502-503.	1.1	9
317	The width of the basement membrane does not influence clinical presentation or outcome of thin glomerular basement membrane disease with persistent hematuria. Kidney International, 2010, 78, 1041-1046.	2.6	9
318	Endotoxaemia in Haemodialysis: A Novel Factor in Erythropoetin Resistance?. PLoS ONE, 2012, 7, e40209.	1.1	9
319	Dialysate bacterial endotoxin as a prognostic indicator of peritoneal dialysis related peritonitis. Nephrology, 2016, 21, 1069-1072.	0.7	9
320	Plasma Mitochondrial DNA Level is a Prognostic Marker in Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2016, 41, 402-412.	0.9	9
321	Depression does not predict clinical outcome of Chinese peritoneal Dialysis patients after adjusting for the degree of frailty. BMC Nephrology, 2020, 21, 329.	0.8	9
322	Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlledÂtrial. CKJ: Clinical Kidney Journal, 2021, 14, 991-997.	1.4	9
323	Relation between microRNA expression in peritoneal dialysis effluent and peritoneal transport characteristics. Disease Markers, 2012, 33, 35-42.	0.6	9
324	Podocyte mRNA in the urinary sediment of minimal change nephropathy and focal segmental glomerulosclerosis. Clinical Nephrology, 2015, 84 (2015), 198-205.	0.4	9

#	Article	IF	Citations
325	Peritonitis risk for older patients on peritoneal dialysis. Peritoneal Dialysis International, 2008, 28, 457-60.	1.1	9
326	Role of Î²1 and Î²2 subunits of the interleukin-12 receptor in determining T helper 1/T helper 2 responses in vivo in the rat. Immunology, 2000, 99, 109-112.	2.0	8
327	Prevalence of Psychological Problems in Chinese Peritoneal Dialysis Patients. Hong Kong Journal of Nephrology, 2005, 7, 82-89.	0.0	8
328	Factors Associated with Sudden Death in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 58-63.	1.1	8
329	Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism. Nephrology, 2014, 19, 339-344.	0.7	8
330	Weight change during the first year of peritoneal dialysis: Risk factors and prognostic implications. Hong Kong Journal of Nephrology, 2015, 17, 28-35.	0.0	8
331	Longitudinal Changes of NF-ÎºB Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients. Scientific Reports, 2020, 10, 6440.	1.6	8
332	Adipose expression of miR-130b and miR-17-5p with wasting, cardiovascular event and mortality in advanced chronic kidney disease patients. Nephrology Dialysis Transplantation, 2022, 37, 1935-1943.	0.4	8
333	Measurements on the routine chest radiograph as prognostic markers in Chinese peritoneal dialysis patients. Clinical Nephrology, 2011, 76, 16-22.	0.4	8
334	Urinary sediment mRNA level of extracellular matrix molecules in adult nephrotic syndrome. Clinica Chimica Acta, 2016, 456, 157-162.	0.5	7
335	Estimation of clinical parameters of chronic kidney disease by exhaled breath full-scan mass spectrometry data and iterative PCA with intensity screening algorithm. Journal of Breath Research, 2017, 11, 036007.	1.5	7
336	The choice of comorbidity scoring system in Chinese peritoneal dialysis patients. Clinical and Experimental Nephrology, 2018, 22, 159-166.	0.7	7
337	The new ISPD peritonitis guideline. Renal Replacement Therapy, 2018, 4, .	0.3	7
338	Beware of drug interaction between tigecycline and tacrolimus. Nephrology, 2020, 25, 99-100.	0.7	7
339	Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritisâ€"which target should we choose?. Rheumatology, 2020, 59, 2881-2892.	0.9	7
340	Relation between number of prescribed medication and outcome in peritoneal dialysis patients. Clinical Nephrology, 2006, 66, 256-262.	0.4	7
341	The role of vascular endothelial growth factor in peritoneal hyperpermeability during CAPD-related peritonitis. Peritoneal Dialysis International, 2002, 22, 265-7.	1.1	7
342	The impact of social support on the survival of Chinese peritoneal dialysis patients. Peritoneal Dialysis International, 2008, 28, 252-8.	1.1	7

#	Article	IF	Citations
343	Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trial. Lupus, 2022, 31, 488-494.	0.8	7
344	Intravenous versus subcutaneous EPO: Anything to do with pure red cell aplasia complication. American Journal of Kidney Diseases, 2003, 41, 266-267.	2.1	6
345	Assessment of Protein Nitrogen Appearance in Chinese Peritoneal Dialysis Patientsâ€"Which Method to Use?. Renal Failure, 2003, 25, 235-246.	0.8	6
346	Uraemic tumoural calcinosis. Nephrology Dialysis Transplantation, 2004, 19, 505-506.	0.4	6
347	Rapid Progression of Destructive Spondyloarthropathy. Spine, 2005, 30, E31-E33.	1.0	6
348	The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism. CKJ: Clinical Kidney Journal, 2009, 2, 205-212.	1.4	6
349	Treatment of Pulmonary Embolism by Subcutaneous Low-Molecular- Weight Heparin in a Hemodialysis Patient. American Journal of Nephrology, 1998, 18, 325-328.	1.4	5
350	Oral Anticoagulant and Dental Procedures. Archives of Internal Medicine, 2003, 163, 2532.	4.3	5
351	The Changing Face of Peritonitis. Peritoneal Dialysis International, 2004, 24, 413-415.	1.1	5
352	Influence of Emergency Room Fee on Acute Stroke Presentation in a Public Hospital in Hong Kong. Neuroepidemiology, 2004, 23, 123-128.	1.1	5
353	Peritoneal Protein and Albumin Excretion as Markers of Cardiovascular Risk and Systemic Endothelial Dysfunction. Hong Kong Journal of Nephrology, 2004, 6, 31-37.	0.0	5
354	Characteristics and Outcomes of Chronic Kidney Disease Patients Who Default on Appointments at a Low Clearance Clinic. Hong Kong Journal of Nephrology, 2011, 13, 33-38.	0.0	5
355	Haemoglobin variability in Chinese pre-dialysis CKD patients not receiving erythropoietin. Nephrology Dialysis Transplantation, 2011, 26, 2919-2924.	0.4	5
356	Polycystic Kidney Disease Presenting With Hypertension and Hypokalemia. American Journal of Kidney Diseases, 2012, 59, 270-272.	2.1	5
357	Endotoxemia in Peritoneal Dialysis Patients: A Pilot Study to Examine the Role of Intestinal Perfusion and Congestion. Peritoneal Dialysis International, 2017, 37, 111-115.	1.1	5
358	Exploring the Link Between Hepatic Perfusion and Endotoxemia in Hemodialysis. Kidney International Reports, 2021, 6, 1336-1345.	0.4	5
359	Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculosis mycobacterium â€“ A single centre experience spanning 20 years. Peritoneal Dialysis International, 2022, 42, 204-211.	1.1	5
360	The impact of increasing the daytime dialysis exchange frequency on peritoneal dialysis adequacy and nutritional status of Chinese anuric patients. Peritoneal Dialysis International, 2002, 22, 197-203.	1.1	5

#	Article	IF	Citations
361	Nephrotoxicity related to new therapeutic compounds. Renal Failure, 2005, 27, 329-33.	0.8	5
362	Successful medical eradication of tuberculous paranephric abscess in renal transplantation. Nephrology Dialysis Transplantation, 1999, 14, 1288-1290.	0.4	4
363	A confused uraemic woman. Lancet, The, 2001, 357, 278.	6.3	4
364	Severe bone marrow failure associated with the use of alternating steroid with chlorambucil in lupus membranous nephropathy in Chinese. Lupus, 2001, 10, 295-298.	0.8	4
365	Lead nephropathy: early leads from descriptive studies. Internal Medicine Journal, 2006, 36, 678-682.	0.5	4
366	The relationship between bone morphogenic protein-7 and peritoneal transport characteristics. Nephrology Dialysis Transplantation, 2008, 23, 2989-2994.	0.4	4
367	Relationship between Myeloid-Related Protein 8/14 and Survival of Chinese Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 489-496.	0.9	4
368	Relationship between serum levels of tumour necrosis factorâ€related apoptosisâ€inducing ligand and the survival of Chinese peritoneal dialysis patients. Nephrology, 2012, 17, 466-471.	0.7	4
369	Urinary mRNA in Systemic Lupus Erythematosus. Advances in Clinical Chemistry, 2013, 62, 197-219.	1.8	4
370	Long-term outcome of biopsy-proven minimal-change nephrotic syndrome in Chinese children. Hong Kong Journal of Nephrology, 2013, 15, 22-27.	0.0	4
371	Campylobacter Peritonitis Complicating Peritoneal Dialysis: A Review of 12 Consecutive Cases. Peritoneal Dialysis International, 2013, 33, 189-194.	1.1	4
372	Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients. Therapeutics and Clinical Risk Management, 2015, 11, 829.	0.9	4
373	Peritoneal inflammation and fibrosis in Câ€reactive protein transgenic mice undergoing peritoneal dialysis solution treatment. Nephrology, 2017, 22, 125-132.	0.7	4
374	Clinical practice guidelines for the provision of renal service in Hong Kong: Peritoneal Dialysis. Nephrology, 2019, 24, 27-40.	0.7	4
375	The efficacy of managing fluid overload in chronic peritoneal dialysis patients by a structured nurse-led intervention protocol. BMC Nephrology, 2019, 20, 454.	0.8	4
376	Risk of peritonitis after gastroscopy in peritoneal dialysis patients. Peritoneal Dialysis International, 2022, 42, 162-170.	1.1	4
377	Circulating endotoxin and inflammation: associations with fitness, physical activity and the effect of a 6-month programme of cycling exercise during haemodialysis. Nephrology Dialysis Transplantation, 2022, 37, 366-374.	0.4	4
378	Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy. Kidney Medicine, 2021, 3, 76-82.e1.	1.0	4

#	Article	IF	Citations
379	The Clinical Utility of the Neutrophil-to-Lymphocyte Ratio as a Discriminatory Test among Bacterial, Mycobacterium Tuberculosis, and Nontuberculous Mycobacterium Peritoneal Dialysisâ€"Related Peritonitis. Kidney360, 2022, 3, 1031-1038.	0.9	4
380	Urinary mi-106a for the diagnosis of IgA nephropathy: Liquid biopsy for kidney disease. Clinica Chimica Acta, 2022, 530, 81-86.	0.5	4
381	Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients. Scientific Reports, 2022, 12, .	1.6	4
382	Predictors and prognostic significance of persistent fluid overload: A longitudinal study in Chinese peritoneal dialysis patients. Peritoneal Dialysis International, 2023, 43, 252-262.	1.1	4
383	Nonconvulsive status epilepticus in dialysis patients: In Reply. American Journal of Kidney Diseases, 2002, 39, 440-441.	2.1	3
384	Good metabolic control using tacrolimus-based immunosuppressants in primary cadaveric renal transplantation in Chineseâ€ƒ-â€ƒa preliminary report. Clinical Transplantation, 2002, 16, 39-42.	0.8	3
385	Images From Headache. Headache Caused by Pott's Puffy Tumor. Headache, 2003, 43, 916-916.	1.8	3
386	Hospital Arrival after Acute Stroke: Any Better after 10 Years?. Cerebrovascular Diseases, 2004, 17, 346-346.	0.8	3
387	Peritoneal Dialysis-Related Infections. , 2005, , 569-587.		3
388	Vancomycin Concentrations in Autosomal Dominant Polycystic Kidney Disease. Clinical Infectious Diseases, 2005, 40, 205-205.	2.9	3
389	Prevalence and Implications of Isolated Microscopic Hematuria in Asymptomatic Chinese Pregnant Women. Nephron Clinical Practice, 2007, 105, c147-c152.	2.3	3
390	In Reply To â€˜The Beneficial Effect of Oral Calcitriol Treatment on Proteinuria in IgA Nephropathy: Another Point of Viewâ€™. American Journal of Kidney Diseases, 2008, 52, 805.	2.1	3
391	Hyperchloraemic metabolic acidosis. Emergency Medicine Journal, 2008, 25, 613-613.	0.4	3
392	Relationship between HSP70-2 A+1267G Polymorphism and Cardiovascular Events of Chinese Peritoneal Dialysis Patients. Nephron Clinical Practice, 2014, 128, 153-158.	2.3	3
393	Employment status in peritoneal-dialysis patients. Hong Kong Journal of Nephrology, 2016, 18, 11-14.	0.0	3
394	Urinary <scp>mRNA</scp> and lupus disease flare. Nephrology, 2017, 22, 27-30.	0.7	3
395	Peritonitis in Peritoneal Dialysis Patients. , 2017, , 435-447.e1.		3
396	Polymerase chain reaction/electrospray ionizationâ€"mass spectrometry (PCR/ESI-MS) is not suitable for rapid bacterial identification in peritoneal dialysis effluent. Peritoneal Dialysis International, 2021, 41, 96-100.	1.1	3

#	Article	IF	Citations
397	Gene Expression Using the PALM System. Methods in Molecular Biology, 2011, 755, 47-56.	0.4	3
398	2656 Can N-acetylcysteine really prevent contrast-induced nephropathy in patients with chronic renal insufficiency? A randomized study and pooled analysis. European Heart Journal, 2003, 24, 491.	1.0	3
399	The relationship between peritoneal transport characteristics and messenger RNA expression of aquaporin in the peritoneal dialysis effluent of CAPD patients. Journal of Nephrology, 2005, 18, 197-203.	0.9	3
400	Is peritoneal dialysis kinder for the heart?. Peritoneal Dialysis International, 2011, 31, 135-7.	1.1	3
401	Obesity, Weight Gain, and Fluid Overload in Peritoneal Dialysis. , 0, 2, .		3
402	Excessive risk and poor outcome of hospital-acquired peritoneal dialysis-related peritonitis. CKJ: Clinical Kidney Journal, 2022, 15, 2107-2115.	1.4	3
403	A Simple Assessment of Peritoneal Transport in Stable Continuous Ambulatory Peritoneal Dialysis Patients. American Journal of Nephrology, 1998, 18, 311-317.	1.4	2
404	Pharmacokinetic Advantages of Two-Hour Post-Dose Cyclosporin A Level for the Therapeutic Drug Monitoring in Stable Chinese Kidney Transplant Recipients. Nephron Clinical Practice, 2005, 99, c68-c72.	2.3	2
405	Secular trends in the medical discharge summary in an acute medical hospital. Postgraduate Medical Journal, 2006, 82, 615-618.	0.9	2
406	Preventing contrast nephropathy in catheter laboratory. Heart, 2007, 93, 654-655.	1.2	2
407	PSEUDOCLUBBING OF FINGERS. Nephrology, 2007, 12, 206-206.	0.7	2
408	Spironolactone is not Effective for the Treatment of Hypokalemia in Peritoneal Dialysis Patients. Hong Kong Journal of Nephrology, 2007, 9, 36-40.	0.0	2
409	Relationship Between Î²1-Adrenergic Receptor Polymorphisms and Cardiovascular Disease in Peritoneal Dialysis Patients. Hong Kong Journal of Nephrology, 2008, 10, 58-63.	0.0	2
410	Prediction of Outcomes for Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2008, 28, 340-342.	1.1	2
411	Relationship between Î²1â€adrenergic receptor polymorphisms and cardiovascular disease in patients with diabetic nephropathy. Nephrology, 2010, 15, 242-247.	0.7	2
412	In Memoriam of Henry Tenckhoff. Artificial Organs, 2017, 41, 697-699.	1.0	2
413	Concerns regarding ISPD Recommendations for Peritonitis in Relation to Imipenem/Cilastatinâ€"In Reply. Peritoneal Dialysis International, 2017, 37, 585-585.	1.1	2
414	Perspectives on acute kidney injury strategy: Hong Kong. Nephrology, 2018, 23, 104-106.	0.7	2

#	Article	IF	Citations
415	Concerns regarding Inconsistencies within and between ISPD Recommendations for Peritonitis and Catheter-Related Infectionsâ€"In Reply. Peritoneal Dialysis International, 2018, 38, 311-312.	1.1	2
416	Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease. American Journal of Hospice and Palliative Medicine, 2019, 36, 718-721.	0.8	2
417	Relationship between glutathione S-transferase M1 polymorphism and clinical outcomes in Chinese peritoneal dialysis patients. Journal of Nephrology, 2012, 25, 310-316.	0.9	2
418	Near-drowning related acute kidney injury. Clinical Nephrology, 2016, 85 (2016), 305-308.	0.4	2
419	Residual renal function and recovery of renal function. Peritoneal Dialysis International, 2007, 27, 159-61.	1.1	2
420	Thiazolidinediones in peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29, 248-51.	1.1	2
421	Selective internal radiation therapy by yttrium-90 microspheres for hepatocellular carcinoma after renal transplantation. Clinical Transplantation, 2001, 15, 284-288.	0.8	1
422	Muscle infarction in peritoneal dialysis patients1 1Editor Note: The corresponding author declined to respond.. American Journal of Kidney Diseases, 2003, 42, 1102-1103.	2.1	1
423	Hyponatraemia in a woman with a pelvic mass. Postgraduate Medical Journal, 2003, 79, 61-61.	0.9	1
424	Leflunomide and anti-glomerular basement membrane glomerulonephritis: Comment on the letter by Bruyn et al. Arthritis and Rheumatism, 2004, 50, 336-336.	6.7	1
425	The Beneficial Effect of Oral Sodium Bicarbonate in Peritoneal Dialysis Patients â€" How Long Does It Last After Stopping Treatment?. Hong Kong Journal of Nephrology, 2005, 7, 14-21.	0.0	1
426	Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients. Nature Clinical Practice Nephrology, 2006, 2, 672-673.	2.0	1
427	Pancytopenia in a patient with tuberculous peritonitis. Internal Medicine Journal, 2007, 37, 277-278.	0.5	1
428	Dual Therapy with ACE Inhibitors and Angiotensin II Receptor Blockers in Proteinuric IgA Nephropathy Patients. Hong Kong Journal of Nephrology, 2007, 9, 89-93.	0.0	1
429	A lady with unresolved loin pain. Journal of the Royal Society of Medicine, 2008, 101, 85-86.	1.1	1
430	Thiazolidinediones in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 248-251.	1.1	1
431	Concerns regarding the ISPD Guidelines/Recommendations for Peritonitis Due to Mycobacteriaâ€"Response to Bhowmiket al.. Peritoneal Dialysis International, 2011, 31, 365-365.	1.1	1
432	Questioning the effect of Î²-blockers on vascular stiffness. Nature Reviews Nephrology, 2015, 11, 447-448.	4.1	1

#	Article	IF	Citations
433	MO704THE PROGNOSTIC IMPACT OF WEIGHT GAIN AFTER PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
434	Prognostic significance of peritoneal dialysis effluent mitochondrial DNA level. Clinica Chimica Acta, 2021, 519, 1-9.	0.5	1
435	Nodular Lesions on the Hands of an ESKD Patient on Hemodialysis. Kidney360, 2021, 2, 1390-1391.	0.9	1
436	Salt and Water Balance in Peritoneal Dialysis. , 0, , 488-499.		1
437	Menstrual loss of renal function: a case of mefenamic acid induced renal cortical necrosis. Clinical Nephrology, 2016, 86, 162-164.	0.4	1
438	Factors Associated With Use of Telemedicine for Follow-Up of SLE in the COVID-19 Outbreak. Frontiers in Medicine, 2021, 8, 790652.	1.2	1
439	Factors affecting the therapeutic response of enalapril in treatment of post transplant erythrocytosis. Nephrology, 1997, 3, 569-571.	0.7	0
440	Alloimmune hemolytic anemia after ABO-mismatch kidney transplantation: prompt recovery following azathioprine withdrawal. Hong Kong Journal of Nephrology, 2000, 2, 54-56.	0.0	0
441	Early IgA nephropathy: paradigm evolving from a clinical concept into a histological measure. Hong Kong Journal of Nephrology, 2000, 2, 74-78.	0.0	0
442	Nonconvulsive status epilepticus. American Journal of Medicine, 2002, 112, 243-244.	0.6	0
443	Calcifications. Lancet, The, 2002, 360, 442.	6.3	0
444	Peritoneal dialysis in patients with dementia. American Journal of Kidney Diseases, 2003, 42, 212.	2.1	0
445	Secular trend in medical education regarding infectious disease. Medical Education, 2003, 37, 881-883.	1.1	0
446	Nonspecific Guidelines Lead to Inappropriate Fluoroquinolone Use. Archives of Internal Medicine, 2003, 163, 1617.	4.3	0
447	"Question mark" aorta. Postgraduate Medical Journal, 2003, 79, 121-121.	0.9	0
448	Malignant hypertension after adrenalectomy. Nephrology Dialysis Transplantation, 2004, 19, 2919-2920.	0.4	0
449	Myoglobinuric renal failure. Journal of Emergency Medicine, 2004, 26, 461.	0.3	0
450	Destructive spondyloarthropathy. Kidney International, 2006, 70, 237.	2.6	0

#	Article	IF	Citations
451	SUCCESSFUL EMBOLIZATION OF TRANSPLANT KIDNEY ARTERIOVENOUS FISTULA. Nephrology, 2007, 12, 623-624.	0.7	0
452	Peritonitis in Peritoneal Dialysis Patients. , 2008, , 596-613.		0
453	Are spot urine samples adequate for assessment of proteinuria in patients with lupus nephritis?. Nature Clinical Practice Nephrology, 2008, 4, 72-73.	2.0	0
454	Nephrology image: quadriceps rupture. Kidney International, 2009, 75, 568.	2.6	0
455	Quiz Page December 2010. American Journal of Kidney Diseases, 2010, 56, A29-A31.	2.1	0
456	History of Peritoneal Dialysis Solutions. , 2012, , 553-559.		0
457	Pseudohypercalcaemia in patients with heat cramps: implications on clinical practice. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 997-999.	0.2	0
458	Relationship between human oxoguanine-DNA glycosylase-1 polymorphism and the outcome of Chinese peritoneal dialysis patients. Hong Kong Journal of Nephrology, 2012, 14, 24-29.	0.0	0
459	Laparoscopic live donor nephrectomy: Current practice and results of renal transplantation. Surgical Practice, 2012, 16, 17-21.	0.1	0
460	Spurious hypernatraemia. Nephrology, 2013, 18, 531-532.	0.7	0
461	Adequacy of Peritoneal Dialysis in Terms of Small Solute Clearanceâ€"The Evolving Concept. Artificial Organs, 2016, 40, 221-224.	1.0	0
462	Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients. Hong Kong Journal of Nephrology, 2016, 19, 1-6.	0.0	0
463	Therapeutic drug monitoring of onceâ€daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient. Nephrology, 2017, 22, 184-184.	0.7	0
464	Rising to the Challenge of Antimicrobial Resistance. Peritoneal Dialysis International, 2017, 37, 129-130.	1.1	0
465	Letter: chronic kidney disease risk in patients with chronic hepatitis Bâ€"authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 1324-1324.	1.9	0
466	Peritoneal Dialysis-Related Infections. , 2019, , 509-519.e5.		0
467	Peritoneal Dialysis in Diabetic Patients. , 2021, , 247-258.		0
468	Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong. Kidney360, 2021, 2, 721-728.	0.9	0

#	Article	IF	Citations
469	BiliousÂperitonealÂdialysate in a peritoneal dialysis patient. Kidney International, 2021, 100, 485.	2.6	0
470	Images of the month: Crystalglobulin-induced nephropathy. Clinical Medicine, 2020, 20, e125-e126.	0.8	0
471	Title is missing!. , 2020, 15, e0241242.		0
472	Title is missing!. , 2020, 15, e0241242.		0
473	Title is missing!. , 2020, 15, e0241242.		0
474	Title is missing!. , 2020, 15, e0241242.		0
475	Title is missing!. , 2020, 15, e0241242.		0
476	Title is missing!. , 2020, 15, e0241242.		0